Please login to the form below

Not currently logged in
Email:
Password:

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Q&A: Kate Pain

Q&A: Kate Pain

Randy was an American professor who was diagnosed with pancreatic cancer in 2006 and given between three to six months to live.

Latest news

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    8040 in pancreatic cancer and a phase 1 study of the drug with CTLA-4 inhibitor MK-1308 in solid tumours. ... VEGF/FGF/PDGF inhibitor will give an update on lucitanib – also in HR+/HER2- breast cancer.

  • Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer

    The company gave up on a plan to extend the use of abemaciclib into pancreatic cancer earlier this year, and suffered another setback in 2017 when the drug failed to meet ... the mark in the phase 3 JUNIPER study, which was intended to position the drug

  • Cancer Research UK to test Asterias’ lung cancer vaccine Cancer Research UK to test Asterias’ lung cancer vaccine

    Cancer Research UK to test Asterias’ lung cancer vaccine. The vaccine could treat NSCLC patients who are at risk of relapse. ... The charity helped Roche carry out a phase III trial of its peptide-based GV1001 telomerase vaccine in pancreatic cancer

  • Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

    in pancreatic cancer, as well as earlier-stage trials in other advanced solid tumours including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). ... It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and

  • Shire offloads oncology unit to Servier for $2.4bn Shire offloads oncology unit to Servier for $2.4bn

    Shire has agreed to sell its cancer drugs business to French drugmaker Servier for $2.4bn, even as it prepared for a possible takeover offer from Takeda. ... The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase)

More from news
Approximately 22 fully matching, plus 102 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Accelerating innovation Accelerating innovation

    Also on Ipsen’s radar are opportunities in pancreatic cancer, where it’s keen to maintain the momentum gained from Merrimack’s Onivyde. ... Much like its work in liver cancer with Cabometyx, being active in pancreatic cancer allows it to compete in

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    One such example within pancreatic cancer demonstrates how it might be advantageous to take a more strategic outlook on recruitment centres. ... 7) EpiomicTM Patient Segmentation Database, Pancreatic Adenocarcinoma Disease Sub-Population, Pancreatic

  • Porterhouse Medical Group charity round-up for 2017

    Other disease awareness and fund-raising activities were carried out throughout the year for World Cancer Day, MPS Awareness Day, Jeans for Genes Day and World Pancreatic Cancer Day.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics